Q3 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Conclusions Financial performance Immunology Cosentyx® - IL-17A inhibitor NCT05767034 REPLENISH (CAIN457C22301) Polymyalgia rheumatica Indication Phase Phase 3 Patients 360 Primary Outcome Measures Arms Proportion of participants achieving sustained remission Appendix Innovation: Clinical trials Neuroscience Oncology Cosentyx® - IL-17A inhibitor NCT04930094 GCAPTAIN (CAIN457R12301) Giant cell arteritis Phase 3 Indication Phase Patients 348 Primary Outcome Measures Arms Intervention Number of participants with sustained remission Intervention Arm 1 Experimental: Secukinumab 300 mg, randomized in 1:1:1 ratio every 4 weeks Arm 2 Experimental: Secukinumab 150 mg, randomized in 1:1:1 ratio every 4 weeks Arm 3 Placebo randomized in 1:1:1 ratio every 4 weeks Target Patients Adult patients with PMR who have recently relapsed Readout Milestone(s) 2025 Publication TBD Target Patients Experimental: Secukinumab 300 mg Placebo Comparator: Placebo Patients with Giant Cell Arteritis (GCA) Primary 2025 Final 2026 Readout Milestone(s) Publication TBD 53 Investor Relations | Q3 2023 Results References Abbreviations Other NOVARTIS | Reimagining Medicine

View entire presentation